DE69426870T2 - Verfahren zur herstellung von aminochinolinen - Google Patents

Verfahren zur herstellung von aminochinolinen

Info

Publication number
DE69426870T2
DE69426870T2 DE69426870T DE69426870T DE69426870T2 DE 69426870 T2 DE69426870 T2 DE 69426870T2 DE 69426870 T DE69426870 T DE 69426870T DE 69426870 T DE69426870 T DE 69426870T DE 69426870 T2 DE69426870 T2 DE 69426870T2
Authority
DE
Germany
Prior art keywords
aminoquinolines
producing
producing aminoquinolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69426870T
Other languages
English (en)
Other versions
DE69426870D1 (de
Inventor
Nick Nikolaides
J Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of DE69426870D1 publication Critical patent/DE69426870D1/de
Publication of DE69426870T2 publication Critical patent/DE69426870T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DE69426870T 1993-01-29 1994-01-25 Verfahren zur herstellung von aminochinolinen Expired - Lifetime DE69426870T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/011,405 US5395937A (en) 1993-01-29 1993-01-29 Process for preparing quinoline amines
PCT/US1994/000906 WO1994017043A1 (en) 1993-01-29 1994-01-25 Process for preparing quinoline amines

Publications (2)

Publication Number Publication Date
DE69426870D1 DE69426870D1 (de) 2001-04-19
DE69426870T2 true DE69426870T2 (de) 2001-10-25

Family

ID=21750245

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426870T Expired - Lifetime DE69426870T2 (de) 1993-01-29 1994-01-25 Verfahren zur herstellung von aminochinolinen

Country Status (9)

Country Link
US (1) US5395937A (de)
EP (1) EP0681570B1 (de)
JP (1) JP3703829B2 (de)
AU (1) AU677381B2 (de)
DE (1) DE69426870T2 (de)
ES (1) ES2154672T3 (de)
HU (1) HUT73671A (de)
IL (1) IL108424A (de)
WO (1) WO1994017043A1 (de)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6608201B2 (en) * 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
AU776654B2 (en) 1999-01-08 2004-09-16 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1427445A4 (de) * 2001-08-30 2006-09-06 3M Innovative Properties Co Verfahren zur reifung von plasmacytoiden dendritischen zellen unter verwendung von die immunantwort modifizierenden molekülen
CA2462203A1 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
PT1719511E (pt) * 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
PT1487485E (pt) * 2002-03-19 2011-03-11 Powderject Res Ltd Adjuvantes de imidazoquinolina para vacinas de adn
CA2484044A1 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2003237386A1 (en) 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
US6852861B2 (en) 2002-07-23 2005-02-08 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
KR20050030958A (ko) * 2002-07-26 2005-03-31 비오갈 기오기스제르갸르 알티. 신규한 1Ｈ-이미다조[4,5-ｃ]퀴놀린-4-시아노 및1Ｈ-이미다조[4,5-ｃ]퀴놀린-4-카르복스아미드 중간체를통한 1Ｈ-이미다조[4,5-ｃ]퀴놀린-4-아민의 제조 방법
CA2495570C (en) 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール／ヘタリール置換されたイミダゾキノリン
EP2572715A1 (de) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunstimulatorische Kombinationen
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (de) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selektive modulation von tlr-vermittelter biologischer aktivität
EP1601365A4 (de) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylaktische behandlung von uv-induzierter epidermaler neoplasie
BRPI0408125A (pt) * 2003-03-07 2006-03-01 3M Innovative Properties Co 1-amino 1h-imidazoquinolinas
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
AU2004220466A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004091500A2 (en) * 2003-04-10 2004-10-28 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2005011629A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
CA2535117A1 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
AU2004268616B2 (en) * 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658076B1 (de) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
CA2536578A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
AP2006003542A0 (en) * 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050059072A1 (en) * 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
EP1673087B1 (de) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy-substituierte imidazochinoline
SG149829A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2543685A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
EP1686992A4 (de) 2003-11-25 2009-11-04 3M Innovative Properties Co Hydroxylamin- und oxim-substituierte imidazochinoline, imidazopyridine und imidazonaphthyridine
RU2409576C2 (ru) * 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
JP2007513170A (ja) * 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
EP1701955A1 (de) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
AU2005222995B2 (en) 2004-03-15 2010-08-26 3M Innovative Properties Company Immune response modifier formulations and methods
CA2559863A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CN101426524A (zh) * 2004-04-28 2009-05-06 3M创新有限公司 用于粘膜接种疫苗的组合物和方法
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
EP1786450A4 (de) * 2004-08-27 2009-11-11 3M Innovative Properties Co Hiv-immunstimulatorische zusammensetzungen
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US20110070575A1 (en) * 2004-12-08 2011-03-24 Coley Pharmaceutical Group, Inc. Immunomodulatory Compositions, Combinations and Methods
DK2561872T3 (en) 2004-12-17 2014-12-08 Anadys Pharmaceuticals Inc 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
US8461174B2 (en) * 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US9248127B2 (en) * 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
AU2006212765B2 (en) * 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008532933A (ja) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
PL2351772T3 (pl) 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
WO2006091567A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223148A1 (en) 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2605808A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
ITMI20051292A1 (it) * 2005-07-08 2007-01-09 Dipharma Spa Procedimento per la purificazione di imiquimod
EP2614709A1 (de) 2005-07-18 2013-07-17 Novartis AG Kleintiermodell für HCV-Replikation
EP1931352B1 (de) * 2005-08-22 2016-04-13 The Regents of The University of California Tlr-agonisten
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8476292B2 (en) * 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
DK1951299T3 (da) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
EP1948173B1 (de) * 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy- und alkoxy-substituierte 1h-imidazochinoline und verfahren
EP2377552A3 (de) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenzaimpfstoffe mit reduzierter Anzahl von Emulsionshilfsmitteln
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
CA2630463C (en) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
EP1955708A4 (de) 2005-11-24 2013-02-06 Dainippon Sumitomo Pharma Co Neuer memory-ctl-induktionspotentiator
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ570106A (en) 2006-01-27 2012-04-27 Novartis Vaccines & Diagnostic Influenza vaccines containing hemagglutinin and matrix proteins
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1988896A4 (de) 2006-02-22 2011-07-27 3M Innovative Properties Co Konjugate zur modifizierung von immunreaktionen
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2382987A1 (de) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Lagerung von Influenza-Impfstoffen ohne Kühlung
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EP2700638A1 (de) 2006-05-31 2014-02-26 The Regents Of the University of California Purinanaloga
EP2054431B1 (de) 2006-06-09 2011-08-31 Novartis AG Bakterielle adhäsine konformere
MX2008016036A (es) 2006-06-20 2009-04-07 Transgene Sa Vacuna viral recombinante.
US7709448B2 (en) * 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
US20080103310A1 (en) * 2006-10-16 2008-05-01 Janos Hajko Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2677733A1 (en) 2007-02-07 2008-09-25 The Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
EP2185191B1 (de) 2007-06-27 2012-09-12 Novartis AG Influenzaimpfstoffe mit geringem zusatz
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101952282A (zh) 2007-12-20 2011-01-19 诺瓦提斯公司 用作pi 3激酶抑制剂的噻唑衍生物
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
EP2268309B1 (de) 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
PL2364314T3 (pl) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulatory receptorów Toll-podobnych
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
AU2010238255B2 (en) 2009-04-14 2014-10-16 Novartis Ag Compositions for immunising against Staphylococcus aureus
BRPI1011836A2 (pt) * 2009-04-21 2017-05-16 Selecta Biosciences Inc imunonanoterapêuticos que fornecem uma resposta induzida por th1
JP2012525370A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー インフルエンザに対して防御するためのアジュバント添加ワクチン
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP3178490B1 (de) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP2575988A1 (de) 2010-05-28 2013-04-10 Tetris Online, Inc. Interaktive, hybride und asynchrone computerspiel-infrastruktur
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
EP2718292B1 (de) 2011-06-03 2018-03-14 3M Innovative Properties Company Hydrazin-1h-imidazochinolin-4-amine und daraus hergestellte konjugate
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
MX340452B (es) 2011-10-28 2016-07-08 Novartis Ag Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
EP2776069A1 (de) 2011-11-07 2014-09-17 Novartis AG Trägermolekül mit einem spr0096- und einem spr2021-antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
AU2013263043B2 (en) 2012-05-16 2016-06-16 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
EP2869842A1 (de) 2012-07-06 2015-05-13 Novartis AG Immunogene zusammensetzungen und verwendungen davon
EP3024476A1 (de) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
RU2680246C1 (ru) 2013-12-06 2019-02-19 Новартис Аг Схема приема для селективного по альфа-изоформе ингибитора фосфатидилинозитол-3-киназы
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
EP3194401B1 (de) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Feste formen eines toll-like-rezeptormodulators
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
JP2018532750A (ja) 2015-11-02 2018-11-08 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
FR3113287B1 (fr) 2020-08-07 2023-06-23 Phv Pharma Procédé industriel de synthèse de l’imiquimod à partir de la quinolèine-2,4-diol applicable à son utilisation pharmaceutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE242806C (de) *
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
DE69029212T2 (de) * 1989-02-27 1997-05-22 Riker Laboratories Inc 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
WO1992006093A1 (en) * 1990-10-05 1992-04-16 Minnesota Mining And Manufacturing Company Process for the preparation of imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
HU222250B1 (hu) * 1991-03-01 2003-05-28 Minnesota Mining And Manufacturing Company 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható intermedierek

Also Published As

Publication number Publication date
IL108424A (en) 1998-09-24
US5395937A (en) 1995-03-07
HU9501973D0 (en) 1995-09-28
AU6165694A (en) 1994-08-15
ES2154672T3 (es) 2001-04-16
DE69426870D1 (de) 2001-04-19
AU677381B2 (en) 1997-04-24
IL108424A0 (en) 1994-04-12
EP0681570B1 (de) 2001-03-14
WO1994017043A1 (en) 1994-08-04
HUT73671A (en) 1996-09-30
JPH08505881A (ja) 1996-06-25
JP3703829B2 (ja) 2005-10-05
EP0681570A1 (de) 1995-11-15

Similar Documents

Publication Publication Date Title
DE69426870T2 (de) Verfahren zur herstellung von aminochinolinen
DE69407292T2 (de) Verfahren zur herstellung von liposomen
ATE243211T1 (de) Verfahren zur herstellung von dihalogenazolopyrimidinen
DE59604922D1 (de) Verfahren zur herstellung von polyalkoholen
DE69519379T2 (de) Verfahren zur herstellung von trifluorethylene
DE69604277D1 (de) Verfahren zur herstellung von nootkaton
DE59601604D1 (de) Verfahren zur herstellung von n-aryl- und n-hetarylhydroxylaminen
DE59305905D1 (de) Verfahren zur herstellung von n-alkanoyl-polyhydroxyalkylaminen
DE69414253D1 (de) Verfahren zur herstellung von oximin
ATE181554T1 (de) Verfahren zur herstellung von n- phosphonomethylglyzin
DE69327650D1 (de) Verfahren zur herstellung von chlordioxid
DE59401406D1 (de) Verfahren zur herstellung von naphtalocyaninen
DE69408873T2 (de) Verfahren zur herstellung von carbamaten
DE59509620D1 (de) Verfahren zur herstellung von acyloinen
DE59404478D1 (de) Verfahren zur herstellung von polyvinylpyridin-n-oxiden
DE69324697D1 (de) Verfahren zur herstellung von dinitrotoluol
DE69514369T2 (de) Verfahren zur herstellung von pentafluorethan
DE69415648T2 (de) Verfahren zur herstellung von polyfluoropropionylhalogeniden
DE69418472D1 (de) Verfahren zur herstellung von goethit
DE69318307T2 (de) Verfahren zur herstellung von difluormethan
DE69411012T2 (de) Verfahren zur herstellung von cumenhydroperoxyd
DE69308599D1 (de) Verfahren zur herstellung von 2-paradioxanonen
DE69315049D1 (de) Verfahren zur herstellung von alkadienolen
ATA235592A (de) Verfahren zur herstellung von arylhydantoinen
ATA13292A (de) Verfahren zur herstellung von ceftriaxondinatrium-salzhemiheptahydrat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MEDA AB, SOLNA, SE